parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.08 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in salivary ionocytes	0.75
chemistry Open Targets	compounds already reach it: pentoxifylline, dipyridamole	1.00
trials ClinicalTrials.gov	1 Parkinson's trial, 0 stopped	1.00
literature PubMed	3 Parkinson's papers of 146	0.82
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 3399

receipt 3409: PDE1C in dopamine neurons, braak

power: full sample +0.02 (p 0.949, n 18), 95% CI -0.45 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.02 (p 0.949, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.976, n 18). could be the mix.
skeptic: leave-one-out range -0.13 to +0.10, sign flips 4; without severely affected donors +0.02 (p 0.949, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PDE1C in dopamine neurons.

case closed: nothing better to follow up.

receipt 3408: PDE1C in oligodendrocytes, braak

power: full sample +0.11 (p 0.664, n 18), 95% CI -0.38 to +0.55. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.09 (p 0.728, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.20 (p 0.418, n 18). could be the mix.
skeptic: leave-one-out range -0.02 to +0.23, sign flips 1; without severely affected donors +0.11 (p 0.664, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PDE1C in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts